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The steroid and xenobiotic receptor (SXR) (also known as pregnane X receptor or PXR) is a nuclear hormone
receptor activated by a diverse array of endogenous hormones, dietary steroids, pharmaceutical agents, and
xenobiotic compounds. SXR has an enlarged, flexible, hydrophobic ligand binding domain (LBD) which is
remarkably divergent across mammalian species and SXR exhibits considerable differences in its pharmacology
among mammals.The broad response profile of SXR has led to the development of "the steroid and xenobiotic
sensor hypothesis". SXR has been established as a xenobiotic sensor that coordinately regulates xenobiotic
clearance in the liver and intestine via induction of genes involved in drug and xenobiotic metabolism. In the
past few years, research has revealed new and mostly unsuspected roles for SXR in modulating inflammation,
bone homeostasis, vitamin D metabolism, lipid homeostasis, energy homeostasis and cancer.The identification
of SXR as a xenobiotic sensor has provided an important tool for studying new mechanisms through which
diet, chemical exposure, and environment ultimately impact health and disease.The discovery and
pharmacological development of new PXR modulators might represent an interesting and innovative therapeutic
approach to combat various diseases.
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SXR, a steroid and xenobiotic sensor
The mammalian xenobiotic response is mediated primarily
through the activity of four families of cytochrome P450
(CYP) monooxygenases (CYP1, CYP2, CYP3, and CYP4)
[Nelson et al., 1996]. CYP enzymes are the main
enzymatic system for metabolism of lipophilic substrates
of diverse structures and are important in the oxidative,
peroxidative, and reductive metabolism of numerous
endogenous compounds including steroids, bile acids,
fatty acids, prostaglandins, leukotrienes, biogenic amines
and retinoids [Nebert and Russell, 2002;Waxman, 1999].
Among four families of CYP enzymes, the CYP3A family
is one of the most important since it is responsible for the
metabolism of more than 50% of clinically used drugs
and many xenobiotic chemicals [Guengerich, 1999].The
CYP2B family is responsible for another 25-30% of drug
and xenobiotic metabolism [Xie and Evans, 2001].The
ability of organisms to induce P450 enzymes in response
to elevated xenobiotic levels is crucial for their survival
and normal homeostasis.
CYP3A genes are responsible for the initial metabolism
of numerous xenobiotic chemicals, making them a first
line of defense against toxic substances in the diet and
environment. It is notable that a large number of CYP3A
substrates are also capable of inducing or up-regulating
expression of the mRNAs encoding the enzymes
themselves [Denison and Whitlock, 1995; Guengerich,
1999;Wrighton et al., 2000]. Because the CYP3A family
genes produce key enzymes for the metabolism of more
than 50% of prescription drugs, there has been a strong
interest in understanding the mechanistic basis of CYP3A
gene regulation. It is well known that drugs capable of
inducing expression of CYP3A genes are likely to lead
to interactions with other drugs.This is a serious problem
that is compounded by the extreme diversity of the
compounds that are known CYP3A inducers.
In 1998, Blumberg  et al.  [Blumberg and Evans, 1998],
Kliewer  et al.  [Kliewer et al., 1998], and Bertilsson  et
al.  [Bertilsson et al., 1998] isolated cDNAs encoding a
novel orphan nuclear receptor which was subsequently
shown to play a central role in the transcriptional
regulation of CYP3A4. It was named SXR (steroid and
xenobiotic receptor), PXR (pregnane ‘X’ receptor), and
PAR (pregnane activated receptor), respectively by these
groups, and was designated as NR1I2 in the standard
nomenclature [Nuclear Receptors Nomenclature
Committee, 1999]. Despite the different names, this
receptor has properties predicted for a steroid and
xenobiotic sensor as shown by several lines of evidence.
First, SXR is expressed predominantly in liver and
intestine, both sites of steroid and xenobiotic metabolism.
Second, SXR activation directly stimulates the
transcription of CYP enzymes in response to the presence
of its ligands and plays a central role in the transcriptional
regulation of CYP3A4. Moreover, SXR not only regulates
the expression of CYP enzymes such as CYP3A4,
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(e.g., UDP-glucuronosyltransferase (UGT1A1) and
sulfotransferase (SULT)) and ABC family transporters
such as MDR1 and MRP2 [Dussault et al., 2001; Synold
et al., 2001]. Finally, SXR is activated by a diverse array
of pharmaceutical agents including taxol, rifampicin (RIF),
SR12813, clotrimazole, phenobarbital , the herbal
antidepressant St. John’s wort , and peptide mimetic HIV
protease inhibitors such as ritonavir (reviewed in [Dussault
and Forman, 2002; Kliewer et al., 2002]).These studies
indicate that SXR functions as a xenobiotic sensor
[Blumberg et al., 1998; Lehmann et al., 1998] that
coordinately regulates drug clearance in the liver and
intestine via induction of genes involved in drug and
xenobiotic metabolism, including oxidation (phase I),
conjugation (phase II), and transport (phase III) [Dussault
and Forman, 2002; Kliewer et al., 2002].Therefore, we
will use the name SXR to refer to this endobiotic and
xenobiotic sensor throughout this review, rather than the
more commonly used but inaccurate PXR.
Gene knockout studies have confirmed a role for SXR in
regulating the metabolism of endogenous steroids, dietary
and xenobiotic compounds [Staudinger et al., 2001; Xie
et al., 2000a]. At least two types of knockout animals have
been developed. Xie et al. generated SXR knockout mice,
which have a deletion of two exons including amino-acid
residues 63–170 of the DNA-binding domain [Xie et al.,
2000a].The mice produced by Staudinger et al. have a
deletion of the first coding exon, which includes the
translation start site and the first zinc finger of the SXR
DNA-binding domain (amino acids 1 to 63) [Staudinger
et al., 2001]. In both models, complete gene disruption
was confirmed by the absence of SXR expression in the
liver and small intestine where it is predominantly
expressed; although, there are subtle phenotypic
differences between the two types of mice.Targeted
disruption of SXR abolishes the induction of CYP3A
genes in response to prototypic inducers such as
dexamethasone or PCN. Notably, these mice are also
susceptible to severe liver damage induced by toxic bile
acid such as lithocholic acid (LCA).The loss of
hepatoprotection to bile acids results from aberrant
regulation of genes involved in the biosynthesis, transport,
and metabolism of bile acids including cholesterol
7α-hydroxylase (CYP7A1) and the Na
+-independent
organic anion transporter 2 (OATP2).This indicates that
SXR plays a critical role in both xenobiotic and bile acid
detoxification.
SXR gene and protein structure
The SXR gene consists of nine exons and spans
approximately 35 kb in chromosome 13q12-13.3 (Figure
1a).Three alternatively spliced transcripts that encode
different isoforms of SXR have been described.Transcript
variant 1 encodes two products (isoforms 1l and 1s)
through the use of alternative translation initiation codons,
which are in the same reading frame (Figure 1b).
Transcript variant 2 encodes the longest isoform and
initiates translation from the standard AUG codon present
in its 5' terminal exon.Variant 3 contains an alternate 5'
terminal exon, and uses a different acceptor splice site
at exon 5 in comparison to transcript variant 2. It initiates
translation from an in-frame, downstream non-AUG (CUG)
codon, resulting in a shorter isoform 3 with a different
N-terminus and is also missing an internal segment,
compared to isoform 2 (Figure 1b). All three isoforms are
present at varying levels in the liver and gut. Isoform 3 is
largely non-responsive to ligands in transient transfection
assays [Gardner-Stephen et al., 2004]. Additional
transcript variants derived from alternative promoter
usage, alternative splicing, and/or alternative
polyadenylation may exist, but, they have not been
completely characterized [Fukuen et al., 2002; Lamba et
al., 2004].
Although it shares the same overall arrangement of its
functional domains with other nuclear receptors, in
contrast to most other receptors SXR can bind structurally
diverse ligands. SXR can be activated by a range of
ligands that is almost as diverse as the substrates of
CYP3A4, including many drugs.Yet, SXR can also
display considerable discretion in ligand binding.The
crystal structure of the SXR ligand binding domain (LBD)
reveals its special features [Chrencik et al., 2005;Watkins
et al., 2003a;Watkins et al., 2003b;Watkins et al., 2001].
SXR has three α-helical domains common to other
nuclear receptors. Uniquely, SXR has five strands of
β-sheet, whereas other nuclear receptors typically contain
only two to three strands. SXR has a large insertion of
approximately 60-residues between helices 1 and 3 that
contains two additional β-strands.These extend the usual
two- to three-stranded LBD β-sheet to five strands.This
insert also adds a novel α-helix that folds along the
underside of the SXR ligand-binding pocket.Together,
these elements lead to an enlarged, flexible, hydrophobic
LBD which is capable of fitting large and varied ligands
and that can also change shape depending on the nature
of its bound ligand.The crystal structures of SR12813-
or hyperforin-bound SXR have also been characterized
[Watkins et al., 2003b;Watkins et al., 2001].These
structures show that hyperforin makes more nonpolar
and polar interactions than does SR12813, which helps
to explain the latter’s high affinity binding to SXR.This
study also found that SR12813 is able to interact with
SXR in a variety of different orientations, suggesting that
the ligands can make more than one set of hydrogen
bonds in order to interact with the ligand-binding domain
of SXR.This increases the number of ligands that can
activate SXR. Interestingly, as a main target gene of SXR,
CYP3A4 can also metabolize a wide range of endogenous
compounds and xenobiotics. However, the crystal
structures of un-liganded and substrate-bound CYP3A4
revealed a surprisingly small active site, with little
conformational change associated with the binding of an
inhibitor (metyapone) or substrate (progesterone)
[Williams et al., 2004]. Future studies that investigate the
potential mechanisms of molecular recognition by SXR
and CYP3A4 may help us to understand the complex of
xenobiotic metabolism regulated by SXR-CYP3A4 axis.
Chrencik et al. also described the 2.8 Å crystal structure
of the ligand-binding domain of human SXR in complex
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Review SXR, more than a xenobiotic receptorFigure 1.  Structure of SXR gene, protein and mRNA isoforms. a) The genomic structure of SXR and its three splice variants.The protein coding
regions are depicted as filled boxes and the untranslated 5’ and 3’ regions are shown as white boxes.The horizontal line represents introns. b) The
structure of splice variants of SXR.Variant 1 originates from exon 1a and gives rise to proteins 1l and 1s through the use of the alternative initiation
codons shown by arrows.Variant 2 originates from exon 1b and it makes the longest protein.Variant 3 represents an in-frame deletion of 111bp at the
5’ end of exon 5 (shown by white box).The arrows depict translation initiation codon. c) Single nucleotide polymorphisms (SNPs) in SXR. Fifteen known
non-synonymous SNPs of SXR are represented by * and arranged according to their position on the wild-type (variant 1l) SXR protein.The DNA and
ligand binding domains of the protein are shown in black boxes.
with rifampicin, one of the largest known ligands for the
receptor [Chrencik et al., 2005].They found that the
macrocyclic ring of rifampicin fits within the SXR
ligand-binding pocket. In contrast, the drug’s
4-methyl-1-piperazinyl ring and several protein loops are
disordered.Their observations suggest that the structural
flexibility of SXR allows it to respond to large ligands by
changing the effective size of its ligand-binding pocket.
This highlights the key role that structural flexibility plays
in SXR's promiscuous response to xenobiotics.Their
structure also provides insights into the selective response
to rifampicin exhibited by SXR from different species.
Very recently, Xue et al. and colleagues presented a
crystal structure for the SXR LBD in complex with
T0901317 (T1317), which is also an agonist of another
nuclear receptor, liver X receptor (LXR) [Xue et al.,
2007a].They found that despite differences in the size
and shape of the ligand binding pockets, key interactions
with this ligand are conserved between human SXR and
human LXR.The same group subsequently reported the
crystal structure of the human SXR ligand-binding domain
(LBD) in complex with 17β-estradiol, a representative
steroid ligand, at 2.65 Å resolution [Xue et al., 2007b].
They compared the SXR-estradiol complex with other
nuclear receptors, including the estrogen receptor, in
complexes with analogous ligands.The results showed
that the placement of the steroid within the ligand-binding
pocket is remarkably different for SXR compared with
other members of the nuclear receptor superfamily.Their
results provide detailed insights into the manner in which
SXR responds to a wide range of endobiotic compounds.
This suggests that determining the crystal structure of
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method to elucidate how SXR detects and protects the
body from harmful chemicals.
The subcellular localization of SXR is currently
controversial.Two groups have shown that un-liganded
SXR stays predominantly in the cytoplasm and that it
translocates to the nucleus after ligand addition. Based
on microinjection studies and transient transfection
assays, Kawana et al. reported that amino acids 66-92
are important for nuclear import of SXR [Kawana et al.,
2003]. In agreement with these studies, Negishi and
co-workers showed that in the absence of ligand, SXR
resides in a complex with CCRP and heat-shock proteins
(HSPs), remaining in the cytoplasm until ligand binding
which triggers nuclear translocation [Squires et al., 2004].
They also showed that nuclear localization signal (NLS),
xenobiotic response signal (XRS) and AF2 domain are
all required for nuclear translocation of SXR. However,
other studies showed that human SXR is exclusively
nuclear, irrespective of ligand binding [Koyano et al.,
2004; Saradhi et al., 2005].The same results were
obtained by overexpressing GFP-tagged proteins or by
immunostaining transiently or stably-transfected HepG2
cells. Saradhi et al. also could not find any association
between CCRP complex and human SXR [Saradhi et al.,
2005]. Interestingly, they also reported that SXR was
associated with condensed mitotic DNA during mitosis.
We found, using a mouse monoclonal antibody directed
against human SXR that it was localized to the nucleus
in breast cancers in the absence of added ligands [Miki
et al., 2006].
While it is difficult to reconcile these disparate results, it
is notable that the earlier studies showing cytoplasmic
localization employed the rodent receptor [Kawana et al.,
2003; Squires et al., 2004], whereas those showing
nuclear localization used the human receptor [Koyano et
al., 2004; Miki et al., 2006; Saradhi et al., 2005].
Therefore, one possibility is that species differences may
partly explain the different localization. Other possible
explanations could be cell-type specificity and differences
in the specificity of the antibodies employed. Further
studies using other cell types and antibodies of
well-demonstrated specificity (which is largely not the
case with most of the widely used commercial antibodies)
will be required to fully resolve the issue of sub-cellular
localization.
SXR and species-specific xenobiotic
metabolism
SXR can be activated by a wide diversity of natural
steroids (e.g., pregnanes, estranes and androstanes),
dietary compounds (e.g., hyperforin, tocotrienols,
menaquinones), and xenobiotics (e.g., rifampicin,
nifedipine, PCN). Interestingly, SXR exhibits considerable
differences in its pharmacology among mammals
[Blumberg et al., 1998; Jones et al., 2000; LeCluyse,
2001], which may explain species-specific differences in
xenobiotic induction by CYP3A. Compared with most
other nuclear receptors, SXR is remarkably divergent
across mammalian species with the ligand binding
domains sharing ~70-80% identity compared with the
~90% typically exhibited by orthologous nuclear receptors.
Differences in amino acid sequences among the
mammalian receptors are responsible for species-specific
induction of CYP3A by drugs and xenobiotics [LeCluyse,
2001;Watkins et al., 2001]. One general observation is
that there are significant differences in the xenobiotic
response between humans and rodents and that these
differences are completely explained by the pharmacology
of SXR [Blumberg et al., 1998; Jones et al., 2000; Kliewer
et al., 1998; LeCluyse, 2001; Lehmann et al., 1998; Xie
et al., 2000a; Xie and Evans, 2001]. For example, the
antibiotic rifampicin, the anti-diabetic drug troglitazone
and the cholesterol-reducing drug SR12813 were found
to be effective activators of both human and rabbit SXR,
but had little activity on mouse or rat SXR [Jones et al.,
2000]. In contrast, pregnane 16α-carbonitrile (PCN) was
a more potent activator of rat and mouse SXR than of
human or rabbit SXR [Jones et al., 2000; Masuyama et
al., 2000;Takeshita et al., 2001]. Corresponding induction
of the SXR-inducible CYP3A genes in humans, rats and
rabbits was also observed in primary hepatocytes.The
crystal structure of the SXR LBD suggested which amino
acid differences in the LBD of SXR contributed to species
differences in ligand activation of human vs. mouse
receptor and the consequent induction of CYP3A.
Conversion of four of the polar amino acids in the ligand
binding pocket from the mouse sequence to the
corresponding residues found in the human receptor
resulted in a mutated mouse receptor that showed a
humanized response profile to ligands [Watkins et al.,
2001].
Since species differences exist in ligand specificity
between human and mouse SXR, an important tool for
the study of xenobiotic metabolism was the development
of the “humanized” mouse [Xie et al., 2000a] that
responds to human SXR activators such as rifampicin,
but does not respond to the rodent activator PCN [Ma et
al., 2007; Xie et al., 2000a]. Xie et al. first generated
SXR-null mice containing the human SXR gene driven
by an Albumin (Alb) promoter [Xie et al., 2000a].This
animal is deficient in the mouse SXR gene, while
expressing a human SXR transgene specifically in the
liver. Subsequently, Ma et al. generated a human SXR
mouse model by bacterial artificial chromosome (BAC)
transgenesis in SXR-null mice using a BAC clone
containing the complete human SXR gene and 5'- and
3'-flanking sequences [Ma et al., 2007]. In this hSXR
mouse model, SXR was expressed in both liver and
intestine, and in many (but not all) of the same tissues
where the endogenous gene and its CYP3A target are
expressed (for example, lung is a notable exception).
Treatment of both hSXR models with SXR ligands
mimicked the human response since CYP3As were
induced strongly by rifampicin, a human-specific SXR
ligand, but not by PCN, a rodent-specific SXR ligand [Ma
et al., 2007; Xie et al., 2000a].These models demonstrate
convincingly that SXR is the key regulator of CYP3A
induction by xenobiotics. Moreover, the selective
activation of target genes in response to species-specific
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domain of the receptor, rather than in the DNA-binding
domain or target DNA-binding elements [Ma et al., 2007;
Xie et al., 2000a]. In addition to these two models, Xie et
al. and Gong et al. also generated Alb- and Fatty
Acid-Binding Protein (FABP)-activated hSXR (VP-hSXR)
mice in which constitutively activated hSXR were
expressed in the liver (Alb promoter driven) or in the liver
and intestine (FABP promoter driven), respectively [Gong
et al., 2006; Xie et al., 2000a] .These humanized mice
are a powerful in vivo system to study the roles of human
SXR in xenobiotic metabolism in an animal model.
Natural allelic variants of SXR
SXR displays a broad specificity for a variety of drugs
and is a primary regulator of CYP3A4 induction.The
levels of CYP3A enzymes show considerable sexual
dimorphisms and variation in levels and function among
individuals in the population [Gonzalez, 1992].Variation
in CYP3A expression may lead to important differences
in drug metabolism, leading to clinically significant
differences in drug toxicities and response. It may also
influence the circulating levels of estrogens and the risk
of breast cancer [Kuehl et al., 2001].The molecular
underpinnings of the variations in CYP3A4 expression
are unknown at present, but it is likely that SXR plays a
key role in this process. Approximately 90% of the
inter-individual variability in hepatic CYP3A4 activity is
genetically determined and several CYP3A4 variants
have been reported [Ozdemir et al., 2000]. However, the
reported allelic frequencies and the functional data
demonstrate only a limited role of these variants in
CYP3A4 expression and activity [Eiselt et al., 2001;
Wandel et al., 2000]. Single nucleotide polymorphisms
(SNPs) in SXR should be a major contributor to CYP3A4
expression and activity. Since SXR is a key xenobiotic
‘sensor’ that mediates the physiological response of
multiple drug metabolism genes, identification of
functional polymorphisms in SXR might explain the
variable induction of CYP3A4 and other drug metabolizing
enzymes in response to SXR ligands [Eichelbaum and
Burk, 2001]. It has been reported that different strains of
mice differ substantially in their sensitivity to estrogen
treatment [Spearow et al., 1999]. It is reasonable to
expect that some part of this differential sensitivity may
result from differences in SXR; however, this remains to
be demonstrated.
Several groups have investigated SXR allelic variants in
different ethnic populations. In total, more than 70 SNPs
have been identified so far including 15 in the coding
region that are non-synonymous, creating new SXR
proteins (Figure 1c) [Bosch et al., 2006; Hustert et al.,
2001; King et al., 2007; Koyano et al., 2002; Lim et al.,
2005; Zhang et al., 2001]. Four of the fifteen variants were
located N-terminal to the DNA binding domain (A12T,
E18K, P27S, and G36R) and have no significant effects
on DNA-binding or transactivation compared with
wild-type SXR.Three other variants were located in or
near the DNA binding domain (R98C, K109N, and
R122Q).The variant R98C failed to bind SXR response
element or to transactivate CYP3A4 completely [Koyano
et al., 2004].The variant R122Q also shows significantly
decreased affinity for DNA binding and attenuated
transcriptional activity [Zhang et al., 2001].The variant
K109N has not yet been functionally described.The other
eight variants are within the LBD of SXR (R148Q, Q158K,
D163G, A370T, C379G, R381W and I403V) or close to
the LBD (V140M). R148Q and Q158K are located in helix
1 of the ligand binding domain (LBD). In transient
transfection assays R158Q showed a marked decrease
in activity on the CYP3A4 promoter, whereas R148Q had
no dramatic effect on transactivation ability of SXR
[Koyano et al., 2004; Lim et al., 2005]. Amino acid residue
158 is well conserved among humans, rodent and rabbits,
whereas AA 148 is not [Koyano et al., 2004].The D163G
variant exhibits lower basal activity and an eight-fold
higher induction by rifampicin than wild-type SXR [Hustert
et al., 2001]. In contrast, the variants A370T and V140M
show 1.5-2 fold enhancement in the basal expression of
a CYP3A4 promoter reporter gene, but lack any significant
effect on transcriptional activation.Variants R381W and
I403V have significantly reduced transactivation ability in
comparison to wild-type receptor at 0.3 and 1 micromolar
rifampicin, but had similar ability to that of wild-type at 10
and 20 micromolar rifampicin [Koyano et al., 2004].
Variant C379G has not been functionally described yet,
but as this variant is in the LBD the authors speculated
that this variant could have functional implications [Bosch
et al., 2006].
In addition to SNPs in the protein coding region, two
groups have found significant phenotypic association
between polymorphisms in the promoter region (-566 and
-1359, respectively) of SXR and CYP3A4 expression
[King et al., 2007; Lamba et al., 2008]. A 6-bp deletion in
the promoter region of NR1I2 at a putative hepatic nuclear
factor binding site was suggested to have a possible
influence on the promoter region and potentially inhibit
SXR promoter activity and downregulate expression of
SXR target genes [Lamba et al., 2008; Uno et al., 2003].
Another study reported strong phenotypic correlation
between SNPs in the SXR promoter (at -25385 and
-24381) with inflammatory bowel disease (IBD) [Dring et
al., 2006].
These results are consistent with the possibility that SNPs
in SXR can contribute to the inter-individual variability of
CYP3A4 expression and drug response. However, a
detailed study comparing the activity of all SXR SNPs
toward ligand activation and the potential interactions
between these SNPs and the ability of SXR to modulate
the activity of CAR and other transcription factors remains
to be performed.The relatively modest differences in the
response of SXR harboring non-synonymous SNPs to
ligands suggest that these SNPs are probably not the
sole factors mediating variations in CYP3A expression.
Thus, it is likely that other factors remaining to be
identified are important for individual differences in drug
metabolism. However, considering that SXR plays such
a large role in the regulation of genes involved in drug
metabolism and transport, bile acid detoxification and
cholesterol metabolism, it remains likely that genetic
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important clinical implications. In addition, SXR
polymorphisms could also influence individual
predisposition to tumors caused by environmental
carcinogens, including liver and lung cancer [Forrester
et al., 1990; Paolini et al., 1999].This area of research
also remains largely unexplored.
SXR and natural products
Drug-drug interactions are a common problem in medical
practice and activation of SXR represents the basis for
several clinically important drug-drug interactions.
Compared to drug-drug interaction, drug-nutrient
interactions are less widely considered when prescribing
medications. Modulation of SXR activity by many natural
products has been reported. Below, we summarize the
effects of a few widely consumed natural products on
SXR signaling.
St. John’s wort
St. John’s wort (Hypericum perforatum) is a long-lived,
wild-growing herb that has been used for centuries to
treat a variety of ailments including bruises, dysentery,
jaundice, diarrhea and a wide range of other complaints
[Kumar et al., 2000]. In recent years, St. John’s wort has
become increasingly used as an herbal alternative to
antidepressant drugs for the treatment of mild to moderate
clinical depression. It also is used to treat anxiety,
seasonal affective disorder, and sleep disorders [Gaster
and Holroyd, 2000; Linde et al., 1996]. St. John’s wort
contains a dozen major components; however, hyperforin
is believed to be the key compound responsible for the
herb’s antidepressant effects [Bhattacharya et al., 1998;
Laakmann et al., 1998].There is accumulating evidence
that St. John’s wort interacts with a variety of drugs. In
2000, two groups identified hyperforin as a natural ligand
for SXR [Moore et al., 2000;Wentworth et al., 2000]. St.
John’s wort is able to enhance the transcriptional activity
of SXR comparably to rifampicin. It can also promote
recruitment of the coactivator SRC-1 to SXR and
displaces radiolabeled ligand bound to SXR, suggesting
a direct interaction with the receptor. Of the two putative
active constituents of SJW, hyperforin but not hypericin
induces transcriptional activation and SRC-1 recruitment
by SXR [Moore et al., 2000;Wentworth et al., 2000].
These data suggest that SXR activation by St. John’s
wort mediates its adverse interactions with other drugs.
Vitamin E
Vitamin E is an essential nutrient with antioxidant activity.
Vitamins E comprise a family of eight members, α-, β-,
γ-, and δ-tocopherols and α-, β-, γ-, and δ-tocotrienols.
All forms of vitamin E are initially metabolized by
ω-oxidation, a reaction catalyzed by cytochrome P450
(CYP) enzymes.Tocopherols and tocotrienols differ in
their side chain in that the tocopherols have an
unsaturated phytol side chain, whereas tocotrienol side
chains possess double bonds at the 3’, 7’ and 11’
positions [Kamat et al., 1997; Parker et al., 1993; Saito
et al., 2003]. α-tocopherol is reported to be the most
abundant form of Vitamin E in nature and has the highest
biological activity as a vitamin in humans [Brigelius-Flohe
and Traber, 1999].Tocotrienols are minor plant
constituents especially abundant in palm oil, cereal grains
and rice bran that can provide a significant source of
vitamin E activity [Sen et al., 2000]. Compared with
tocopherols, the biology of tocotrienols has been poorly
studied. Interestingly, all four tocotrienols were found to
be able to specifically bind to and activate SXR, whereas
tocopherols neither bind nor activate [Landes et al., 2003;
Zhou et al., 2004].Tocotrienols also selectively regulate
the SXR target gene CYP3A4 in hepatic and intestinal
cell lines, due to different expression levels of nuclear
receptor corepressor NCoR in hepatic and intestinal cells
[Zhou et al., 2004].The ability of tocotrienols to regulate
SXR target genes in a tissue-specific manner suggests
that tocotrienols are selective SXR modulators and future
development of compounds that selectively activate SXR
target genes in certain tissues will be possible.
Sulforaphane
Sulforaphane (SFN) is one of the most biologically active
phytochemicals in the human diet. SFN is present at high
concentrations in some cruciferous vegetables, especially
in broccoli and broccoli sprouts [Kushad et al., 1999;
Zhang et al., 1992]. Epidemiologic and clinical studies
have indicated that diets high in cruciferous vegetables
protect against a number of cancers [Murillo and Mehta,
2001] and numerous studies in animal models and human
cells support the putative chemopreventive effects of SFN
as an active component in cruciferous vegetables [Chung
et al., 2000; Conaway et al., 2002; Zhang et al., 1994].
The mechanisms of action of the putative
chemopreventive effects of SFN appear to be
multifactorial. SFN can induce apoptosis and cell cycle
arrest in human cancer cells [Gamet-Payrastre et al.,
2000], and is an inhibitor of histone deacetylases [Myzak
et al., 2006]. SFN can also activate the Keap1/Nrf2
transcriptional factor complex that can bind to the
antioxidant response element (ARE) and induce a series
of detoxification enzymes.These include
NAD(P)H:quinone oxidoreductase-1 (NQO1), certain
GSTs and UDP-glucuronosyltransferases (UGTs), and
other genes involved in antioxidant response [Conaway
et al., 2002; Fahey and Talalay, 1999; Gao and Talalay,
2004;Talalay et al., 1995].
Interestingly, it has also been reported that SFN
downregulated CYP3A4 transcription and enzymatic
activity in cultured human hepatocytes, suggesting
another mechanism that could also contribute to its
anti-cancer effects [Maheo et al., 1997]. It was reported
recently that SFN is a specific antagonist of SXR and
inhibits SXR-mediated induction of drug clearance [Zhou
et al., 2007]. SFN efficiently inhibits SXR-mediated
transcription of the CYP3A4 gene in a
concentration-dependent manner. SFN bound directly to
SXR and inhibited SXR-coactivator interactions. SFN
inhibited SXR-mediated CYP3A4 expression and
CYP3A4-mediated midazolam (MDZ) clearance in human
primary hepatocytes.Thus, SFN is the first naturally
occurring antagonist identified for SXR.These findings
point to a novel and complementary mechanism by which
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reduction in CYP3A4-dependent reactive metabolite
formation.These findings could also lead to potentially
important new therapeutic and dietary approaches to
reduce the frequency of adverse drug reactions that are
secondary to SXR-mediated induction of drug clearance
via CYP3A4, MDR1 and other genes regulated in part by
SXR.
Other natural products
Many other natural products that have been shown to
activate SXR include gugulipid, kava kava, paclitaxel,
Coleus forskohlii, Hypoxis, Sutherlandia, qing hao, wu
wei zi and gan cao.The impact of those products on SXR
activities and drug metabolism has been discussed in
detail in an excellent review to which the reader is referred
[Staudinger et al., 2006].
SXR and the osteoprotective action of
Vitamin K2
In addition to its high expression levels in the liver and
intestine, SXR is also expressed at lower levels in the
kidney and lung [Miki et al., 2005], bone [Tabb et al.,
2003], and immune cells such as T cells, B cells, and
mononuclear cells [Albermann et al., 2005; Owen et al.,
2004; Siest et al., 2008]. It is not clear at present what
role SXR is playing in other tissues. Interestingly, SXR is
also expressed in osteosarcoma cell lines and SXR
functions as a mediator of bone homeostasis in addition
to its role as a xenobiotic sensor [Tabb et al., 2003].
Vitamin K2, a critical nutrient required for blood
coagulation, plays an important role in bone formation.
Vitamin K2 supplementation upregulates the expression
of bone markers, increases bone density in vivo, and is
used clinically in the management of osteoporosis.Tabb
et al. showed that vitamin K2 can also act as a
transcriptional regulator of gene expression in
osteosarcoma cells [Tabb et al., 2003].Vitamin K2 bound
to and activated SXR and induced expression of the SXR
target genes in osteosarcoma cells.Vitamin K2 treatment
of osteosarcoma cells increased mRNA levels for the
osteoblast markers bone alkaline phosphatase,
osteoprotegerin, osteopontin and matrix Gla protein.The
known SXR activators, rifampicin and hyperforin, induced
this panel of bone markers to a similar extent, as did
Vitamin K2.Vitamin K2 was able to induce bone markers
in primary osteocytes isolated from wild-type murine
calvaria, but not in cells isolated from SXR knockout
animals.
To explore the SXR-mediated vitamin K2 signaling
network, Ichikawa et al. identified several novel SXR
target genes in osteoblastic cells using microarray and
quantitative real-time PCR [Ichikawa et al., 2006].They
found that tsukushi, matrilin-2, and CD14 antigen are
primary SXR target genes and that all three genes have
bone-related functions. For example, collagen
accumulation in osteoblastic cells was enhanced by
vitamin K2 treatment and tsukushi, a small leucine-rich
proteoglycan, contributes to this process, as
demonstrated by gain- and loss-of-function analyses.
Their results suggest a new function for vitamin K2 in
bone formation as a transcriptional regulator of
extracellular matrix-related genes involved in the collagen
assembly.Very recently, Igarashi et al. showed that
vitamin K2 induces osteoblast differentiation through
SXR-mediated transcription control of Msx2, an
osteoblastogenic transcription factor [Igarashi et al.,
2007]. Upon activation by vitamin K2, SXR can be
recruited together with a coactivator, p300, to the SXR
response element in the Msx2 promoter. Knock-down of
either SXR or Msx2 abolishes the effect of vitamin K2 on
osteoblastic differentiation.Taken together, these lines
of evidence show that the osteoprotective action of
vitamin K2 is largely mediated through the activation of
SXR, and that SXR plays a novel and unexpected role
as a mediator of bone homeostasis. An important
implication of this discovery is that a subset of SXR
activators may function as effective therapeutic agents
for the management of osteoporosis.
SXR and bile acid homeostasis
Bile acids are end products of hepatic cholesterol
catabolism.They function as solubilizing detergents and
play an important role in the digestion and absorption of
lipids in the small intestine. Apart from the beneficial roles
of bile acids, certain bile acids are toxic at high
concentrations and secondary bile acids, especially
lithocholic acid (LCA), are thought to participate in the
pathogenesis of liver disease and colon cancer
[Nagengast et al., 1995]. An intriguing link between SXR
and bile acid homeostasis was uncovered by the
discovery that the highly toxic LCA and its 3-keto
metabolite can efficiently activate SXR [Staudinger et al.,
2001; Xie et al., 2001]. Moreover, co-treatment of mice
with LCA and the known activator, PCN, dramatically
reduced the liver damage caused by LCA in wild-type
mice as assessed by histology and serum levels of liver
enzymes. No such hepatoprotection by PCN was detected
in SXR null mice treated with LCA [Staudinger et al.,
2001]. Mice expressing a constitutively active form of
human SXR were also protected against LCA toxicity [Xie
et al., 2001].This suggests that SXR plays an important
role in bile acid metabolism and protects against LCA
toxicity in mouse liver.This notion was supported by the
phenotype of SXR–FXR double knockout mice. Mice
lacking both FXR and SXR exhibit more severe
disturbances in cholesterol, lipid and bile acid metabolism
than mice lacking only one of the two nuclear receptors
[Guo et al., 2003].Transgenic mice expressing
CYP3A4-LacZ show significant induction of CYP3A4 and
increases levels of 6-β hydroxylated bile acids when they
undergo bile duct ligation, confirming the physiological
relevance of induction of CYP3A4 in cholestatic conditions
[Stedman et al., 2004].
Bile acid homeostasis through SXR is maintained by both
feed-forward and feed-back mechanisms. Activation of
SXR downregulated expression of CYP7A1, the first and
rate limiting step in the metabolism of cholesterol to bile
acids [Staudinger et al., 2001; Xie et al., 2001]. Inhibition
of CYP7A1 is not mediated through SHP as in the case
www.nursa.org  NRS  | 2009 |  Vol. 7 |  DOI: 10.1621/nrs.07001 | Page 7 of 21
Review SXR, more than a xenobiotic receptorfor FXR. Instead, it results from the interaction of SXR
with PGC1α [Bhalla et al., 2004; Li and Chiang, 2005].
Bile acid induced activation of SXR also upregulates the
expression of genes involved in bile acid metabolism and
transport, such as MRP2, OATP2 and CYP3A [Frank et
al., 2005; Guo et al., 2003; Kast et al., 2002;
Kullak-Ublick, 2003]. MRP2 and OATP2 transport bile
acids across canalicular and sinusoidal membranes,
respectively, and CYP3A enzymes hydroxylate bile acids
including LCA. Hydroxylation of LCA by CYP3A produces
more polar 6α- and 6β-hydroxyl derivatives, which are
more soluble and more easily renally secreted.Thus,
activation of SXR maintains bile acid homeostasis both
by repressing synthesis and by increasing metabolism
and excretion by inducing CYP3A, OATP2 and MRP2
expression.
SXR, cholesterol metabolism and lipid
homeostasis
The link between SXR and cholesterol homeostasis was
uncovered when it was found that not only secondary bile
acids, but also bile acid intermediate sterol compounds
such as 5-cholestanoic acid-3,7,12-triols,
7α-hydroxy-4-cholesten-3-one and 4-cholesten-3-one
can activate SXR. Indeed, bile acid precursors are
endogenous ligands for SXR [Dussault et al., 2003].
Activation of SXR by these sterol compounds induces
CYP3A expression and provides an alternative pathway
for sterol clearance in CYP27A1 null mice [Dussault et
al., 2003; Goodwin et al., 2003]. CYP27A1 catalyzes the
cleavage of cholesterol side chains in classic bile acid
biosynthetic pathway and the hydroxylation of cholesterol
to 27-hydroxycholesterol (27-HOC) and
3β-hydroxy-5-cholestenoic acid in most tissues [Chiang,
1998; Russell, 2003]. Interestingly, the sterol
intermediates of bile acid synthesis are more potent
activators of mouse SXR than human SXR, which may
explain the development of cerebrotendinous
xanthomatosis (a neurodegenerative disease caused by
deposition of cholesterol in various tissues) in humans
with CYP27A1 deficiency, but not in corresponding
knockout mice.The role of SXR in cholesterol clearance
and homeostasis was further underlined by the finding
that SXR null mice developed acute hepatorenal failure
when they were fed a diet containing high cholesterol and
cholic acid levels.This suggested that SXR plays an
important role in the detoxification of cholesterol
metabolites [Sonoda et al., 2005]. In agreement with this
finding, it was recently shown that SXR can directly
mediate CYP27A1 expression in cultured intestinal cells
[Li et al., 2007].The activity of CYP27A1 was confirmed
by increased levels of 27-HOC in rifampicin treated cells.
Moreover, the authors showed that SXR can also induce
ABCA1 and ABCG1 expression and promote cholesterol
efflux in the same cells.
In addition to playing important roles in cholesterol
detoxification, SXR can also modulate SREBP-dependent
and SREBP–independent lipogenic pathways in vitro and
in vivo. SXR can mediate a SREBP-independent lipogenic
pathway by activating the free fatty acid (FFA) uptake
transporter CD36, PPARγ, and several accessory
lipogenic enzymes, such as stearoyl CoA desaturase-1
(SCD-1) and long-chain free fatty acid elongase (FAE)
[Zhou et al., 2006c]. SXR activation is also associated
with induction of Insig-1, a protein with anti-lipogenic
properties, and with reduced protein levels of the active
form or SREBP-1 [Roth et al., 2008]. A functional SXR
binding site was found in the Insig-1 promoter and it was
suggested that Insig-1 induction by SXR could lead to
decreased levels of active SREBP-1 and reduced
triglyceride synthesis.These two studies showed opposite
effects of SXR activation on lipid homeostasis, suggesting
that further research will be required to sort out the details.
Yet the overall findings are consistent with a role for SXR
in mediating lipid homeostasis at multiple levels.
Although these studies indicate that SXR plays important
roles in cholesterol detoxification and lipid homeostasis,
it is not clear what effects, if any, long-term SXR activation
has on cholesterol levels in human or in animal models.
Interestingly, studies have shown that SXR activation can
affect serum HDL-C and ApoA-I levels [Bachmann et al.,
2004; Masson et al., 2005]. Induction of CYP3A by some
SXR ligands was positively correlated with induction of
ApoA-I mRNA and plasma HDL and ApoA-I levels in mice
[Bachmann et al., 2004]. However, their interpretation
that SXR is involved is complicated by the finding that
the human specific ligand, rifampicin, which lacks the
ability to activate the rodent receptor, gave positive
results.This suggests that a non-SXR dependent
mechanism may be at work.
Another study showed that the inhibitory effects of bile
acids on HDL and ApoA-I levels were much more
pronounced in SXR null mice, whereas these effects were
blocked in transgenic humanized mice [Masson et al.,
2005]. However, many clinically-relevant SXR ligands
have been shown to increase cholesterol levels. For
example, treatment with the potent and specific SXR
ligand rifampicin has hyperlipidemia as a side effect
[Khogali et al., 1974]. Patients treated with rifampicin for
6 days had an elevated ratio of lathosterol to cholesterol,
indicating increased cholesterol synthesis [Lutjohann et
al., 2004]. In addition, treatment of HIV patients with
ritonavir, one of the first commercially available HIV
protease inhibitors and a potent SXR activator, can cause
hyperlipidemia and may be associated with increased
risk of cardiovascular disease [Barbaro, 2006; Carr et al.,
1998a; Carr et al., 1998b; Shafran et al., 2005]. Cafestol,
presented in unfiltered brewed coffee and the most potent
cholesterol-elevating compound known in the human diet
was recently found to be an agonist of both SXR and
farnesoid X receptor (FXR) [Ricketts et al., 2007]. Cafestol
can induce intestinal CYP27A1 and ABCA1 expression
and promotes cholesterol efflux to the liver via SXR
activation, which is consistent with SXR effects in
intestinal cells [Li et al., 2007].
Several clinical studies have shown that a mixed green
vegetable and fruit beverage containing broccoli can lower
cholesterol levels in hypercholesterolemic patients [Suido
et al., 2002;Takai et al., 2003] and a pilot study indicated
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reduce total cholesterol and LDL cholesterol levels in 12
healthy subjects [Murashima et al., 2004]. SFN is present
at high concentrations in broccoli and broccoli sprouts
and is a naturally occurring antagonist for human SXR
[Zhou et al., 2007].Therefore, it would be of great interest
to investigate whether SFN is the active ingredient in
broccoli that lowers cholesterol levels and whether it does
so by inhibiting SXR activity.
Taken together, these studies suggest that SXR plays
important roles in cholesterol metabolism and lipid
homeostasis. However, the precise mechanisms through
which SXR modulates lipid metabolism and cholesterol
levels in vivo remain unclear.The discovery and
pharmacological development of new selective SXR
modulators could represent an interesting and innovative
therapeutic approach to combat hyperlipidemia and
atherosclerosis.
Interplay between SXR and other
nuclear receptors
In addition to directly regulating expression of its own
target genes, SXR can interact with other nuclear
receptors to exert more complex effects on gene
regulation. Crosstalk between SXR and several other
nuclear receptors has been described, including
constitutive androstane receptor (CAR), farnesoid X
receptor (FXR), vitamin D receptor (VDR), small
heterodimer partner (SHP), hepatocyte nuclear factor 4α
(HNF4α), liver X receptor (LXR) and PPARγ. Here we
discuss the crosstalk between SXR and CAR, FXR and
VDR, all of which appear to be important for xenobiotic,
bile acid, or vitamin D metabolism and disposition.
SXR and CAR
The orphan receptor CAR (NR1I3) was initially isolated
and shown to activate a DR-5 type of retinoid acid
response element (βRARE) in a ligand-independent
manner, suggesting that CAR activates the response
element in the absence of retinoic acid [Baes et al., 1994].
Unlike SXR, CAR shows relatively high basal activity to
transactivate genes without ligand.The role of CAR as
a xenobiotic receptor was first identified by the ability of
selective androstane metabolites to inhibit its constitutive
activity [Forman et al., 1998] and by phenobarbital to
potentiate its activity [Wei et al., 2000]. Its role in positive
xenobiotic regulation was suggested when CAR was
shown to activate the PBREM found in promoters of
phenobarbital-inducible CYP2B genes [Honkakoski et
al., 1998]. It was found later that CAR has a broad role
in xenobiotic metabolism by regulating additional phase
I and phase II enzymes, as well as drug transporters [Xie
and Evans, 2001].
Interestingly, SXR and CAR share a variety of ligands
and activate an overlapping set of genes. For example,
phenobarbital can also bind to and activate SXR. CAR
can regulate CYP3A genes through SXR response
elements and SXR can regulate CYP2B genes via
adaptive recognition of the phenobarbital response
element (PBRE), as revealed by receptor-DNA binding
analysis and transfection assays [Xie et al., 2000b].The
cross-regulation of these two receptors was further
evaluated in vivo. Constitutively active SXR (VP-SXR)
transgenic mice showed sustained induction of CYP3A
and CYP2B [Xie et al., 2000a; Xie et al., 2000b]. However,
constitutively active CAR (VP-CAR) transgenic mice
showed only CYP2B induction; CYP3A was unchanged
[Saini et al., 2004]. It was subsequently shown that CAR
only exhibits very weak binding and functional activation
of the CYP3A4 promoter, instead showing a pronounced
selectivity for CYP2B6 over CYP3A4 [Faucette et al.,
2006].These findings suggest that although SXR and
CAR cross-regulate each other’s expression, that this
cross-regulation of target genes is asymmetric.
SXR and FXR
Farnesoid X receptor (FXR) was originally identified as
a receptor activated by farnesol [Forman et al., 1995].
Subsequent studies have convincingly shown that FXR
functions as a bile acid receptor [Wang et al., 1999]. Bile
acid activated FXR represses the expression of CYP7A1
and CYP2B, enzymes involved in bile acid synthesis,
through an indirect mechanism. Bile acids activate FXR
and induce the expression of small heterodimer partner
(SHP), which binds to and inhibits the activity of liver
receptor homolog-1 (LRH-1), which normally activates
CYP7A1. In addition to inhibiting the activity of LRH-1,
SHP can also interact with SXR and inhibit its
transcriptional activity [Ourlin et al., 2003]. SXR and FXR
not only share bile acid ligands, but they also regulate
some common target genes such as SULT2A1 and MRP2
[Echchgadda et al., 2004; Kast et al., 2002]. SXR can
also directly regulate SHP expression [Frank et al., 2005]
and FXR regulates CYP3A4 transcription through two
functional FXR response elements in the promoter of
CYP3A4 [Goodwin et al., 1999]. Interestingly, SXR can
be also transcriptionally regulated by FXR [Jung et al.,
2006]. Feeding mice with cholic acid or the synthetic FXR
agonist GW4064 resulted in strong induction of SXR
expression.This effect was lost in FXR knockout mice
[Jung et al., 2006]. Four FXR binding elements were
identified in the SXR promoter; two of these were able to
bind FXR protein and trigger a strong response to ligand
treatment.The crosstalk between SXR and FXR leads
to an efficient protection of the liver against bile acid
induced toxicity. Bile acids activate FXR, which
downregulates synthesis of bile acids and also leads to
the transcriptional activation of SXR, thereby promoting
bile acid metabolism.
SXR and VDR
Vitamin D exerts important biological functions in the
maintenance of calcium homeostasis and in the
development and maintenance of bones. Its active
metabolite, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3),
elicits most of its effects through activation of the vitamin
D receptor (VDR) [Jones et al., 1998; Omdahl and May,
2004].The balance between bioactivation and
degradation of 1,25(OH)2D3 is critical for ensuring
appropriate biological effects of Vitamin D.
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catabolism of 1,25(OH)2D3 and appears to be responsible
for controlling intra-renal and systemic 1,25(OH)2D3
levels. CYP24 is directly regulated by VDR and it is
expressed mainly in the kidney where VDR is also
abundant. Although there is also a relatively high level of
VDR expression in the small intestine, constitutive CYP24
expression in this tissue is very low or undetectable, in
contrast to that in the kidney [Xu et al., 2006].
It is well recognized that long-term therapy with some
antiepileptic drugs, including phenobarbital, phenytoin
and carbamazepine, and the antimicrobial agent
rifampicin (RIF), can cause a metabolic bone disease –
osteomalacia [Andress et al., 2002; Burt et al., 1976;
Karaaslan et al., 2000; Pack and Morrell, 2004; Shah et
al., 1981]. Interestingly, many of the drugs that cause
osteomalacia are able to activate SXR, suggesting a
possible connection.To reveal the mechanism of
drug-induced osteomalacia, several groups recently
investigated the impact of SXR activation on CYP24 gene
expression in vitro and in vivo.
Pascussi et al. first suggested that activation of SXR can
enhance the expression of the VDR target gene, CYP24,
which would increase the catabolism of 1,25(OH)2D3;
thereby, leading to drug-induced osteomalacia [Pascussi
et al., 2005].They conducted a series of in vitro and in
vivo studies which were interpreted as providing evidence
that a drug, which can activate SXR is likely to enhance
CYP24 expression and the catabolism of 25(OH)D3,
leading to vitamin D deficiency. However, this model is
of questionable significance with regard to the
physiological functions of CYP24 in vivo, because CYP24
is found primarily in the kidney, where SXR is expressed
at very low levels. In addition, CYP24 is expressed at
very low levels in liver and intestine where SXR is
abundant [Xu et al., 2006].This suggests that enhanced
CYP24 expression by SXR is unlikely to play an important
role in the development of osteomalacia following
long-term treatment with SXR activators.
In accord with this prediction, it was subsequently
reported that CYP3A4, and not CYP24, played the
dominant role in 23- and 24-hydroxylation of 1,25(OH)2D3
under constitutive and induced conditions in human small
intestine and liver [Xu et al., 2006].
Heterologously-expressed CYP3A4 catalyzed the 23-
and 24-hydroxylation of 1,25(OH)2D3; moreover, CYP3A4
exhibited opposite product stereochemical preference
compared with that of CYP24A. Although the metabolic
clearance of Vitamin D3 by CYP3A4 was less than that
catalyzed by CYP24, comparison of metabolite profiles
and experiments using CYP3A-specific inhibitors indicated
that CYP3A4 was the dominant source of 1,25(OH)2D3
23- and 24-hydroxylase activity in both human small
intestine and liver [Xu et al., 2006].
It was later shown that activation of SXR did not induce
CYP24 expression in vitro or in vivo, nor did it
transactivate the CYP24 promoter [Zhou et al., 2006a].
Instead, SXR was shown to be able to crosstalk with VDR
to inhibit VDR-mediated CYP24 promoter activity.This
provided a mechanism to explain the low levels of CYP24
expression in tissues containing high levels of SXR.
1,25(OH)2D3-induced CYP24 expression was enhanced
in SXR knockout mice, and treatment of humans with the
SXR agonist rifampicin had no effect on intestinal CYP24
expression, despite marked CYP3A4 induction [Zhou et
al., 2006a]. Furthermore, feeding WT mice with diet
containing the mouse SXR ligand, PCN, for two weeks
strongly induced SXR target genes CYP3A11, GSTA1,
and MDR1a expression, but failed to induce CYP24
expression in both liver and intestine (Zhou, C.,
unpublished observation). Interestingly,
phenobarbital-activated SXR can also inhibit expression
of CYP2D25 at the transcriptional level [Hosseinpour et
al., 2007]. CYP2D25 is an important 25-hydroxylase
involved in 1,25(OH)2D3 biosynthesis. Downregulation
of CYP2D25 provides another potential new mechanism
for drug-induced osteomalacia.
Taken together with the findings that CYP3A4, and not
CYP24, dominated the hydroxylation of 1,25(OH)2D3 in
human liver and intestine, these results indicate that SXR
plays multiple roles in mediating vitamin D catabolism
and drug-induced osteomalacia. It upregulates CYP3A4
expression, while repressing CYP24 and CYP2D25
expression in the liver and intestine.
SXR, NF-κB and inflammatory bowel
disease (IBD)
SXR and NF-κB
It has long been known that inflammation and infection
reduce hepatointestinal drug metabolism capacity [Aitken
et al., 2006] and that exposure to xenobiotic chemicals
can impair immune function. For example, expression of
hepatic CYP genes can be profoundly decreased by
various infectious and inflammatory stimuli, with
concomitant clinical and toxicological consequences
[Morgan, 1997]. Meanwhile, drug metabolism-inducing
xenobiotics/drugs, such as the antibiotic rifampicin and
the anticonvulsant phenytoin, have immunosuppressive
side-effects [Badawy et al., 1991; Paunescu, 1970;
Scheinfeld, 2003; Sorrell and Forbes, 1975; Sorrell et al.,
1971]. However, the molecular mechanisms underlying
both of these phenomena have remained largely unknown
until recently.Two groups recently revealed a crosstalk
between SXR and NF-κB, providing a potential molecular
mechanism that links xenobiotic metabolism and
inflammation [Gu et al., 2006; Xie and Tian, 2006; Zhou
et al., 2006b].
Zhou et al. reported that activation of SXR by RIF and
other agonists antagonized the activity of NF-κB, in vitro
and in vivo. SXR inhibited NF-κB-mediated reporter
activity and the expression of NF-κB target genes. Mice
deficient in SXR showed increased expression of NF-κB
target genes in multiple tissues and also had marked
intestinal inflammation [Zhou et al., 2006b]. Activation of
NF-κB also inhibited SXR activity and the expression of
SXR target genes. Inhibition of NF-κB also enhanced the
activity of SXR and the expression of its target genes
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activation by lipopolysaccharide (LPS) and tumor necrosis
factor-α (TNFα) plays a pivotal role in the suppression of
CYP3A4 through interactions of NF-κB with the SXR-RXR
complex [Gu et al., 2006]. Inhibition of NF-κB by
NF-κB-specific suppressor SRIκBα reversed the
suppressive effects of LPS and TNFα. Furthermore, they
also performed electrophoretic mobility shift assay
(EMSA) and chromatin immunoprecipitation assays
(ChIP) and showed that NF-κB p65 disrupted binding of
the SXR-RXR complex to its binding motif.Thus, the
negative crosstalk between SXR and NF-κB not only
reveals the possible mechanism underlying the
immunosuppressive effects of RIF, but also explains the
well recognized decreased expression of hepatic CYP
genes during inflammation or infection.
Although transrepression by nuclear receptors and
crosstalk between nuclear receptors and other signaling
pathways have been extensively studied, the molecular
mechanisms are still far from being completely understood
[De Bosscher et al., 2003]. For instance, many plausible
models have been proposed for the crosstalk between
NF-κB and GR, and each of them is supported by
experimental evidence.The models are mutually
inconsistent in many ways and the topic remains highly
controversial [Almawi and Melemedjian, 2002; McKay
and Cidlowski, 1999].The study by Gu et al. [Gu et al.,
2006], which demonstrated direct interaction of NF-κB
with RXR, provided a potential molecular mechanism for
the crosstalk between NF-κB and other nuclear receptors,
since RXR is a common partner for many nuclear
receptors including CAR, VDR, RAR, TR, LXR and
PPARs [Xie and Tian, 2006]. It was also found recently
that transrepression of NF-κB target genes by another
nuclear receptor, PPARγ, is mediated by SUMOylation
of PPARγ [Pascual et al., 2005]. Interestingly, the SXR
ligand-binding domain also contains a consensus
SUMOylation site, but it is currently unknown whether
SUMOylation of SXR is involved in transrepression of
NF-κB signaling.
SXR and inflammatory bowel disease (IBD)
As a key regulator of inflammation, activated NF-κB is
frequently detected in various inflammatory diseases and
tumors [Greten et al., 2004; Karin and Greten, 2005;
Pikarsky et al., 2004]. Zhou et al. observed increased
pro-inflammatory gene expression in SXR KO mice, which
is likely due to the loss of repression of NF-κB by SXR
in vivo [Zhou et al., 2006b].They also found that the small
bowel of SXR knockout mice exhibits a prominent,
increased chronic inflammatory infiltrate.This histological
pattern of a mucosal mononuclear inflammatory infiltrate
is reminiscent of that seen in humans with inflammatory
bowel diseases such as Celiac disease [Kagnoff, 2005;
Wahab et al., 2002].
An independent study conducted by Gonzales et al. also
demonstrated that activation of SXR ameliorates
experimentally-induced inflammatory bowel disease via
inhibition of NF-κB [Shah et al., 2007].They treated
wild-type and SXR knockout mice with the SXR agonist
pregnenolone-16α-carbonitrile (PCN) or vehicle while
administering 2.5% dextran sulfate sodium (DSS) in
drinking water to induce IBD. PCN-treated mice were
protected from DSS-induced colitis compared with
vehicle-treated mice in wild-type mice, but not in SXR KO
mice. PCN treatment did not increase epithelial barrier
function; however, it did decrease mRNA levels of several
NF-κB target genes in a SXR-dependent manner.Their
study clearly demonstrates a protective role for SXR
agonists in DSS-induced IBD and suggests that
SXR-mediated repression of NF-κB target genes in the
colon is a critical mechanism for decreasing the
susceptibility of mice to DSS-induced IBD [Shah et al.,
2007].
Another study showed that dysregulation of the SXR gene
may critically influence intestinal barrier defense and
susceptibility to IBD [Langmann et al., 2004].They further
showed, using DNA microarray analyses of nonaffected
tissue from IBD patients, that expression of SXR and a
known target gene, MDR1, were downregulated in the
colon of ulcerative colitis patients. Although the
downregulation of MDR1 in IBD patients may be
independent of the decreased expression of SXR, these
data are consistent with the possibility that dysregulation
of SXR in the gut is likely to contribute to the
pathophysiology of ulcerative colitis.
In accord with these findings, several clinical studies have
found that the SXR gene is associated with susceptibility
to inflammatory bowel disease [Dring et al., 2006;
Martinez et al., 2007]. Dring et al. showed significant
associations of two SXR SNPs (-23585 and -24381) with
IBD, Crohn's disease (CD), and ulcerative colitis (UC) in
a study of 422 patients with IBD and 350
ethnically-matched controls [Dring et al., 2006].Two other
SNPs (7635 and 8055) were associated with IBD and
CD, but not UC. However, a subsequent case-control
study failed to replicate the original association in a
different population [Ho et al., 2006]. Ho et al. performed
a genome-wide association study in total of 387 UC and
328 CD patients, together with 338 healthy controls and
did not find any association between SXR and IBD.
Most recently, Martínez et al. analyzed three SXR
polymorphisms, including the one most strongly correlated
with IBD risk in their initial study (-25385 and the 6
haplotypes), in 365 UC and 331 CD patients compared
with 550 ethnically-matched controls [Martinez et al.,
2007].They found that the overall haplotypic distribution
showed a significant difference between UC and CD
patients. Patients with extensive UC carrying the -25385T
allele showed increased susceptibility to IBD compared
with healthy subjects.Their data also support the
association of the SXR locus with extensive UC and the
interaction between SXR and MDR1 genes. Larger
studies in other populations may help to clarify the
association between SXR and susceptibility to IBD.
Further characterization of the effects of SNPs on SXR
function in vitro and in vivo will be necessary for a full
understanding of what role SXR plays in IBDs.
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So far, it has become clear that SXR regulates induction
of many drug-metabolizing enzymes and
drug-transporters.These metabolic enzymes and
transporters are involved in biotransformation and
clearance of more than 60% of non-prescription and
prescription drugs, including widely used anti-cancer
agents. Activation of SXR has been associated with
clinically important drug-drug interactions.These
interactions are even more important in oncology, as
cancer patients are typically treated with combinations of
anti-cancer agents. It is also very common to give such
patients many prophylactic and palliative treatments
including anti-emetics, analgesics and glucocorticoids at
the same time to relieve symptoms and decrease
hypersensitivity.
Many of these drugs, including chemotherapeutic agents
themselves, activate SXR. For example, the anti-estrogen,
tamoxifen, and its metabolite 4-hydroxy tamoxifen, widely
used to treat estrogen-positive breast tumors, are potent
activators of SXR [Nagaoka et al., 2006]. Similarly, many
taxane and non-taxane microtubule-stabilizing drugs such
as taxol, epothilone B and BMS-247550 activate SXR
significantly [Mani et al., 2005].The glucocorticoid
dexamethasone, the anti-convulsant phenytoin and the
antibiotic rifampicin also activate SXR potently [Luo et
al., 2002]. As many of the above-mentioned drugs are
given in combination with each other, or other
antineoplastic agents, it is clinically relevant that the SXR
activators can change the bio-availability and
pharmacokinetics of these drugs by inducing their own
metabolism and excretion, as well as that of other
concomitantly administered drugs.
The induction of metabolism and excretion by anti-cancer
agents through SXR has also been associated with
drug-resistance or lower efficacy of these agents in
cancer. For example, the work done by Baker and
coworkers shows that activation of SXR by anti-neoplastic
agents in osteosarcoma cell lines induces activity of
CYP3A4 and MDR1, which provides a possible
mechanism for drug resistance in these cells
[Mensah-Osman et al., 2007]. Similarly, activation of SXR
in endometrial cancer cell lines by many
endocrine-disrupting chemicals has been shown to induce
CYP3A4/CYP3A7 expression [Masuyama et al., 2003].
Further studies by this group showed that when SXR
expression is downregulated in endometrial cancer cells,
the cell growth inhibitory and apoptotic activities of
anticancer agents that activate SXR, such as paclitaxel
and cisplatin, are significantly enhanced. In contrast, SXR
overexpression causes significant decrease in cell growth
inhibition and apoptosis mediated by these agents
[Masuyama et al., 2007]. Paclitaxel has been identified
as a substrate of CYP3A4 and MDR1 [Sparreboom et
al., 1997] and the role of MDR1 in mediating paclitaxel
resistance in tumors has also been shown [Penson et al.,
2004].Therefore, it was suggested that SXR
downregulation might be a way to sensitize these cells
to paclitaxel and overcome their resistance to it through
the inhibition of drug metabolism and/or transport/efflux
of this drug [Masuyama et al., 2007]. Interestingly, these
authors also found that there is a significant inverse
correlation between SXR expression and estrogen
receptor (ER) expression in endometrial tissues.
Moreover, they found that downregulation of SXR
significantly enhanced the proliferation of endometrial
cancer cells in the presence of estradiol. Because
estradiol is a substrate for CYP3A4 and an SXR activator,
it is plausible that local estrogen levels in endometrial
tissue may be controlled by SXR.Thus, SXR
downregulation would reduce expression of CYP3A4,
thereby increasing local estrogen levels and/or increasing
sensitivity of estrogen receptor to estradiol [Cheng et al.,
2001].
A similar inverse relationship between SXR and ER
expression has also been shown in breast cancer cell
lines [Dotzlaw et al., 1999]. Expression of SXR has
recently also been found in breast cancer tissues, but not
in normal surrounding tissues of the patients [Miki et al.,
2006], while other investigators find expression of SXR
in both normal and cancerous breast tissue [Dotzlaw et
al., 1999].The link between SXR and ER warrants further
evaluation to determine whether SXR modulates estrogen
levels only by affecting the metabolism and transport of
estradiol, by directly modulating expression of the
estrogen receptor itself or through some other
mechanism. Similarly, it will be important to determine
the relationship between SXR expression and breast
cancer and to understand whether activating SXR
promotes, or inhibits the growth of breast cancer cells.
Recent studies have shown that expression of the
constitutively active form of SXR (VP-SXR) sensitizes
transgenic mice and colon cancer cells to the oxidative
toxicant paraquat [Gong et al., 2006].This finding was
paradoxical because mice expressing activated SXR have
increased GST activity, and GSTs play an important role
in detoxification of products from oxidative stress.Thus,
a protective effect, rather than apoptosis was expected
in mice expressing high levels of GST. Furthermore,
another study showed that the survival rate of mice
receiving paraquat significantly rose with pretreatment
with phenytoin, phenobarbital, or rifampicin, which
induced activity in CYP3A, CYP2B, or CYP2C [Shimada
et al., 2002].This study suggested that postmitochondrial
fractions play an important role in paraquat detoxication
metabolism, and that the combination of CYP induction
is highly useful for the survival of paraquat-exposed mice.
Interestingly, Gong et al. found that the hepatic activities
of two antioxidative enzymes, superoxide dismutase
(SOD) and catalase (CAT), are downregulated in VP-SXR
mice and in WT mice treated with a SXR agonist, which
can potentially explain the paraquat sensitivity [Gong et
al., 2006]. SOD and CAT may not be direct transcriptional
targets of SXR and the mechanism of SXR-mediated
downregulation of SOD and CAT activities remains to be
determined.Therefore, the cytotoxic effects of SXR in
combination with oxidative stressors such as paraquat
needs to be further investigated.
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that many microtubule-stabilizing agents activate SXR
[Mani et al., 2005]. Interestingly, the compounds which
did not cause microtubule stabilization and cytotoxicity
also did not activate SXR. Although there is no obvious
causal link known between microtubule stabilization and
SXR activation, the association suggests that SXR itself
may be linked with the cytotoxic effects of these drugs
[Mani et al., 2005].We have found that activation of SXR
decreases the growth rate and induces apoptosis in many
breast cancer cell lines [Verma et al.]. As SXR is a major
regulator of steroid, endobiotic and xenobiotic levels in
the body, it will be very important to understand its precise
function in cancer tissues, particularly in hormone




Considering the possible roles of SXR activation in
cancer, and the numerous xenobiotic compounds that
are SXR activators, the relationship between SXR and
endocrine-disrupting chemicals (EDCs) is very interesting.
The term EDCs was coined at a meeting in 1991, chaired
by Theo Colborn, in which she first introduced the concept
that chemical exposure might be altering reproductive
function and fertility in wildlife and humans.This concept
was further emphasized in “Our Stolen Future”, which
summarized the scientific literature on the potential effects
of exposure to persistent chemicals on humans and
wildlife [Colborn et al., 1996].While the doses of individual
chemicals required to elicit such effects remain
controversial, it is beyond dispute that chemical exposure
during sensitive windows of development can cause
wide-ranging disturbances in development and
physiology. EDCs have been defined as exogenous
agents that interfere with the synthesis, secretion,
transport, binding, action, or elimination of natural
hormones in the body, which are responsible for the
maintenance of homeostasis, reproduction, development,
and/or behavior [Kavlock et al., 1996].
Some of the most well known examples of EDCs are 17-α
ethinylestradiol (the contraceptive pill), dioxins,
polychlorinated biphenyls (PCBs), polycyclic aromatic
hydrocarbons (PAHs), furans, phenols, organotins (e.g.,
tributyltin chloride) and various organochlorine pesticides
(e.g., DDT and its derivatives, endosulfan, and dieldrin).
EDCs can disrupt endocrine function directly by activating
or antagonizing the steroid hormone receptors or indirectly
by modulating the function of other nuclear receptors
involved in metabolism, transport, or elimination of steroid
hormones.
The most well-studied effects of EDCs on the endocrine
system are those that result from their activity on estrogen
or androgen receptors [Kelce et al., 1994; Kelce et al.,
1995; Klotz et al., 1996; Sohoni and Sumpter, 1998; Soto
et al., 1994;White et al., 1994]. However, there are a
variety of other mechanisms by which EDCs can disrupt
endocrine function.These include interfering with thyroid
and retinoid receptor function, by interfering with activities
of other nuclear hormone receptors such as SXR, CAR
and PPARγ, and by altering cofactor recruitment
(reviewed in [Grun and Blumberg, 2006; Grun and
Blumberg, 2007;Tabb and Blumberg, 2006]).
Many EDCs including bisphenol-A, organochlorine and
organophosphate pesticides, alkylphenols, phthalates
and PCBs have been shown to upregulate CYP3A
expression and activate SXR [Coumoul et al., 2002; Hurst
and Waxman, 2004; Jacobs et al., 2005; Lemaire et al.,
2004; Masuyama et al., 2000;Tabb et al., 2004;Takeshita
et al., 2001]. For example, phthalic acid and nonylphenol,
the industrial chemicals used in preparation of detergents
and perfumes act as xenoestrogens, and also activate
SXR-mediated transcription and induce CYP3A1 levels
in rat liver [Masuyama et al., 2000].
Similarly, organochlorine pesticides such as endosulfan,
chlordane, and dieldrin activate human SXR and induce
CYP3A4 transcription [Coumoul et al., 2002]. Since many
EDCs can activate SXR and thereby influence their own
metabolism as well as the metabolism of other xenobiotic
and endobiotic compounds, it will be important to
investigate the effects of systemic exposures to EDCs
on SXR activity and characterize the in vivo
pharmacokinetic effects on other compounds.
Similar to other SXR ligands, some EDCs also have
species-specific effects on SXR. For example,
bisphenol-A, the monomer for polycarbonate plastics and
epoxy resins is a human selective SXR activator
[Takeshita et al., 2001]. Highly chlorinated PCBs such as
PCB184 and PCB197 are rodent-selective activators, but
human-selective SXR antagonists [Tabb et al., 2004].To
our knowledge, PCBs are the first example of ligands
acting as agonist on a particular receptor in one species
and antagonist in its orthologous receptor in other
species.
Numerous compounds, many of which are EDCs, can
affect the activity of SXR. A current list of other known
EDCs reported to alter rodent or human SXR activity is
summarized in Table 1.This is an expected response if
that SXR functions as a sensor that induces the
expression of xenobiotic metabolizing enzymes and
transporters, which mediate the body’s response to
harmful dietary and environmental compounds. Most of
these EDCs are also substrate for CYP action. One
implication of this is that activation of SXR and induction
of the xenobiotic response will induce metabolism of these
chemicals.This may reduce their availability and activity
in the body. However, compounds that induce CYPs in
human hepatocytes may also lead to pro-carcinogen
activation and disrupt normal endocrine function. For
example, methoxychlor, an organochlorine pesticide, is
not estrogenic in itself, but its metabolism by CYPs
converts it to a metabolite that is estrogenically active
[Mikamo et al., 2003]. Similarly, some of the hydroxyl
metabolites of PCBs are significantly more powerful
biologically than their parent compound [Kester et al.,
2000; Sandau et al., 2000].
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Review SXR, more than a xenobiotic receptorTable 1.  EDCs that modulate the activity of human and/or rodent
SXR. The table shows an updated list of EDCs that either activate or
inhibit human and/or rodent SXR. EDCs that can modulate SXR activity
are indicated by “+” and EDCs that do not modulate SXR activity are
indicated by “-”. EDCs that are newly-added in the list after the review
done by Kretschmer et al. in 2005 (Kretschmer and Baldwin, 2005) are
written in italics.
Inhibition of SXR activity by chemicals such as highly
chlorinated PCBs will reduce metabolism of endo- and
xenobiotic compounds, as well as the metabolism of the
antagonists themselves. Antagonism of SXR activity by
EDC could have a high biological impact by decreasing
metabolism and elimination (and increasing the blood
levels) of endobiotic and xenobiotic compounds in the
body. Increased levels of these compounds in the body
will increase their potential to affect other hormone
receptors (e.g., the estrogen and androgen receptors).
Therefore, even low-level exposure to SXR antagonists
could lead to a potentially toxic buildup of xenobiotic
chemicals in the body. Jacob et al. have suggested an
in silico model for testing the ability of various compounds
to potentially alter the activity of several nuclear hormone
receptors [Jacobs, 2004]. It is more likely that combining
in silico approaches with cell-based and in vivo testing of
compounds in humanized rodent models will give the
most significant and relevant information to predict the
effects of environmental compounds on humans. Given
that EDCs and other xenobiotic compounds can both
activate and antagonize SXR, it will be increasingly
important to understand the effects of mixtures in order
to predict the effects of real-world chemical exposure.
SXR, FoxO1, FoxA2, and energy
homeostasis
FoxO1 and FoxA2 are members of the “forkhead” family
of transcription factors that play critical roles in lipid
metabolism and gluconeogenesis in the liver [Montminy
and Koo, 2004]. FoxO1 promotes gluconeogenesis in
liver in the fasted state by activating gluconeogenic genes,
such as phosphoenolpyruvate carboxykinase 1
(PEPCK1), glucose-6-phosphatase (G6P) and insulin-like
growth factor-binding protein 1. Foxa2 is a key switch
that regulates fatty-acid breakdown in the liver during
fasting. Long term phenobarbital treatment is known to
reduce plasma glucose levels and to improve insulin
sensitivity in diabetic patients [Lahtela et al., 1985]. By
performing mammalian cell-based two-hybrid screening,
Kodama et al. identified FoxO1 as a coactivator to CAR-
and SXR-mediated transcription [Kodama et al., 2004].
FoxO1 can directly bind to CAR and SXR in a
ligand-dependent manner and facilitate their
transcriptional activity. Interestingly, CAR and SXR act
as corepressors of FoxO1 and downregulate
FoxO1-mediated transcription by preventing its binding
to its response elements in target genes. In addition to
inhibiting FoxO1 activity, drug-activated SXR and CAR
were also shown to inhibit HNF4α transcriptional activity
via squelching of PGC1α, thereby repressing transcription
of PEPCK1 and G6P [Miao et al., 2006].These data show
that drug and glucose metabolisms, two major liver
functions that can be regulated independently, are
reciprocally coregulated by crosstalk between xenobiotic
sensors and hepatic transcription factors.
When blood glucose levels are low after fasting or
prolonged exercise, the liver provides energy to
extra-hepatic tissues and organs via β-oxidation and
ketogenesis [Eaton et al., 1996]. FoxA2 promotes
ketogenesis and β-oxidation by upregulating transcription
of genes including mitochondrial
3-hydroxy-3-methylglutartate-CoA synthase 2 (HMGCS2)
and carnitine palmitoyltransferase 1A (CPT1A) during
fasting or after prolonged exercise [Wolfrum et al., 2004].
FoxA2 is phosphorylated and inactivated by the Akt
pathway and decreases lipid metabolism in response to
insulin.Treatment with drugs such as phenobarbital can
also repress lipid metabolism in an insulin-independent
manner [Kiyosawa et al., 2004]. Nakamura et al. reported
that SXR can crosstalk with FoxA2 to mediate
drug-induced repression of lipid metabolism in fasting
mouse livers [Kiyosawa et al., 2004]. Using wild-type and
SXR
-/- mice, they showed that treatment with PCN
reduced steady-state mRNA levels of HMGCS2 and
CPT1A in wild-type, but not in SXR-deficient mice. A
series of biochemical and cell-based assays
demonstrated that SXR directly represses the ability of
FoxA2 to induce expression of HMGCS2 and CPT1A.
The SXR ligand binding domain can directly interact with
DNA-binding domain of FoxA2 and this interaction
www.nursa.org  NRS  | 2009 |  Vol. 7 |  DOI: 10.1621/nrs.07001 | Page 14 of 21
Review SXR, more than a xenobiotic receptorprevents the binding of FoxA2 to its response elements
in target genes.The crosstalk between SXR and FoxO1
and FoxA2 indicates that SXR not only regulates hepatic
drug metabolism, but also plays important roles in glucose
and energy homeostasis.These results have implications
for the design of new drugs to treat insulin resistance and
diabetes.
Conclusions
SXR was originally described in 1998 as a xenobiotic
sensor that plays important roles in regulating the
metabolism and excretion of a large variety of endobiotic,
dietary, and xenobiotic chemicals. Its function in drug and
xenobiotic metabolism has been extensively studied by
many laboratories and much is known about SXR target
genes and its interaction with other nuclear receptors.
Several new avenues of research have been opened in
recent years that have revealed new and mostly
unsuspected roles for SXR in inflammation, bone
homeostasis, vitamin D metabolism, energy homeostasis
and cancer.These results suggest that SXR has a
number of important functions in the body that remain to
be fully explored. Considering that SXR is activated by
such a wide variety of dietary and xenobiotic chemicals,
they also suggest new mechanisms through which diet,
chemical exposure, and environment ultimately impact
heath and disease.
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